Data cannot be shared publicly because of ethical restrictions. Data are available from Ruijin Hospital Ethics Committee (contact via <wyfkjc@163.com>) for researchers who meet the criteria for access to confidential data.

Introduction {#sec007}
============

Atrial fibrillation (AF) is a growing problem in cardiovascular disease, with age-adjusted incidence rates on the rise \[[@pmed.1003146.ref001]\]. It is predicted that AF prevalence will at least double in the next 30 years \[[@pmed.1003146.ref002],[@pmed.1003146.ref003]\]. Patients with AF have about 5-fold increased risk of ischemic stroke \[[@pmed.1003146.ref004],[@pmed.1003146.ref005]\], which is highly preventable with appropriate oral anticoagulant (OAC) therapy \[[@pmed.1003146.ref006]\]. However, AF may be asymptomatic and unrecognized prior to stroke. Approximately 10% of ischemic strokes are caused by AF that is first detected at the time of stroke \[[@pmed.1003146.ref007]\]. A systematic review showed that unknown asymptomatic AF was common, occurring in 1.4% of those aged 65 years or older on a single--time point check for presence of AF \[[@pmed.1003146.ref008]\], which is also confirmed in a more recent individual patient meta-analysis \[[@pmed.1003146.ref009]\]. It is therefore intuitive that population-based screening for asymptomatic AF and subsequent anticoagulant treatment may be a promising public health strategy to prevent stroke \[[@pmed.1003146.ref010]\].

In China, AF is underdiagnosed and especially undertreated. A multicenter study in China showed that 7.9% of the patients with ischemic stroke and transient ischemic attack (TIA) had newly detected AF, with 3.5% detected by electrocardiography (ECG) and 4.4% detected by 6-day Holter monitoring \[[@pmed.1003146.ref011]\]. The China National Stroke Screening Survey (community-based) data showed that only 2.2% of patients with ischemic stroke and AF were taking OAC at the time of stroke \[[@pmed.1003146.ref012]\]. Our previous study in people aged ≥65 years in Shanghai showed that 88.6% of patients with AF detected by a single--time point ECG were unaware of their disease, and only 1% of these patients were on anticoagulant therapy \[[@pmed.1003146.ref013]\]. According to a recent survey, low OAC rates were related to patients' unawareness that they had AF (26%), lack of AF symptoms (35%), and a lack of understanding of the risks associated with AF (22%) \[[@pmed.1003146.ref014]\].

This study aimed to investigate the prevalence of unknown and untreated AF in residents aged ≥65 years in urban Shanghai and investigate an educational intervention to improve OAC prescription in patients with "actionable AF" (i.e., those identified as newly diagnosed AF or undertreated known AF who have a class 1 recommendation for OAC thromboprophylaxis according to the 2016 European Society of Cardiology (ESC) guidelines (i.e., CHA~2~DS~2~-VASc score ≥ 2 for men or ≥ 3 for women)) \[[@pmed.1003146.ref005]\].

Methods {#sec008}
=======

This study was a prospective cross-sectional study conducted in 5 communities (Yuyuan Community, Laoximen Community, Ruijin Second Road Community, Puxing Community, Sanlin Community) in urban areas of Shanghai from April to September 2017. This study was part of a larger study (AF-CATCH, CT02990741), and the protocol has been previously published in detail \[[@pmed.1003146.ref015]\]. The study was approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiaotong University School of Medicine. Our study was conducted in accordance with the principles of the Declaration of Helsinki. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline ([S1 STROBE](#pmed.1003146.s001){ref-type="supplementary-material"} Checklist).

Study population {#sec009}
----------------

Our study subjects were residents aged 65 years or older recruited from 5 community health centers (Yuyuan Community Health Center, Laoximen Community Health Center, Ruijin Second Road Community Health Center, Puxing Community Health Center, Sanlin Community Health Center) in urban areas of Shanghai from April to September 2017. A description of the community health centers in China is provided in the [S1 Text](#pmed.1003146.s002){ref-type="supplementary-material"}. The screening program was publicized through a public health press conference and media release in Shanghai, official notices of the neighborhood committee, and placement of posters in community health centers. All residents aged 65 years or older were eligible for participation. All participants were informed of the study design and gave their written informed consent before joining the screening program. The consent included agreements to share their information for confidential academic analysis and agreements with the follow-up arrangements in the study.

Screening and intervention {#sec010}
--------------------------

In a screening clinic visit at the community health center, a single-lead (lead I) ECG was recorded for 30 seconds with a handheld ECG device (AliveCor Heart Monitor, now Kardia Mobile). Each ECG rhythm strip was reviewed by a cardiologist from the research team (YC) at the screening visit. The ECGs were classified into 3 groups: sinus rhythm, AF, and uninterpretable. Participants with uninterpretable single-lead ECG were referred for 12-lead ECGs, which were reviewed by a second cardiologist (DW or J-GW). Both AF and atrial flutter diagnosed by ECG were identified as cases of AF. A questionnaire regarding medical history, lifestyle, and use of medications was administered to all participants by the research cardiologists ([S2 Text](#pmed.1003146.s003){ref-type="supplementary-material"}). Participants with a documented history of AF in their medical records from qualified hospitals or with AF recorded on any prior ECG, who were in sinus rhythm on the screening ECG, were defined as "known AF in sinus rhythm." ECGs and medical records obtained outside the study center were documented for verification. Those without AF history or AF rhythm were candidates for an ongoing trial that aims to determine the incidence rate of unknown AF at single--time point screening and during more intensive subsequent screening (AF-CATCH, NCT02990741) \[[@pmed.1003146.ref015]\].

For patients with AF history or AF rhythm, CHA~2~DS~2~-VASc score was calculated to estimate the risk of stroke and determine eligibility for OAC according to the 2016 ESC guidelines (i.e., CHA~2~DS~2~-VASc ≥ 2 for men or ≥ 3 for women: class 1 OAC recommendation) \[[@pmed.1003146.ref005]\]. Details of current antithrombotic treatment were confirmed and recorded using the patients' medical record ([S3 Text](#pmed.1003146.s004){ref-type="supplementary-material"}). All participants not receiving guideline-recommended OAC were deemed actionable AF (including both known AF and newly detected AF) and were included in our educational intervention program. The education program included one-on-one disease education with the research cardiologist at the community health center and provision of educational materials. Education involved communicating that AF is associated with high risk of stroke, the appropriate treatment options, and benefits and risks of anticoagulants. Because warfarin, non--vitamin K OACs, and international normalized ratio (INR) testing are not available at community health centers, patients were advised to attend a specialist clinic for review and OAC prescription. Information on how to make an appointment at a designated specialist clinic near each community was also provided. Across Shanghai, there are over 20 tertiary hospitals with specialist cardiovascular clinics, 10 of which also have a specialist AF clinic. These tertiary hospitals are located between 2 and 10 km from the community health centers and provide the majority of OAC prescription and INR testing for the region.

At 1 month, attendance at the specialist clinic was confirmed via telephone. If they had not attended, we invited them to return for review and another single-lead ECG at the community health center. Education and advice on specialist referral were reinforced.

Follow-up {#sec011}
---------

Follow-up occurred at 12 months in the community health centers. A follow-up questionnaire was administered by the research cardiologist regarding living status; adverse outcomes, including stroke and myocardial infarction, in the past 1 year; whether they attended the AF specialist clinic or not; what treatment they received from specialists, especially in relation to OAC prescription; and, if relevant, why they did not attend the AF specialist clinic ([S4 Text](#pmed.1003146.s005){ref-type="supplementary-material"}). If participants were unable to attend a visit in the community health center, telephone follow-up was offered. If patients had not attended a specialist clinic within the 12-month period, AF education and the importance of attending a designated AF specialist clinic were reinforced.

Statistical analysis {#sec012}
--------------------

Statistical analyses were performed in accordance with our statistical analysis plan using SAS 9.3 (SAS Institute Inc., Cary, NC, United States) \[[@pmed.1003146.ref015]\]. Continuous variables were presented as means with standard deviation (SD), and categorical variables were presented as percentages. New episodes of AF were expressed as true positives divided by the total number screened with accompanying binomial 95% confidence intervals (CIs) calculated using Clopper--Pearson methodology. To assess baseline characteristic differences between the AF patients and non-AF participants, the χ^2^ test or Fisher's exact test was used to compare categorical variables, and Student *t* test was used to compare continuous variables. For all analyses, a two-sided *p*-value \< 0.05 was considered statistically significant.

Results {#sec013}
=======

Characteristics of the study population {#sec014}
---------------------------------------

It is estimated that the 5 participating community health clinics service a total of 9,710 people aged 65 years and over each year. During the study period, 4,784 residents attended the clinic and were approached to participate in the study, and 253 declined (response rate 94.7%). A total of 4,531 citizens (2,530 women \[55.8%\]; mean \[± SD\] age 71.6 ± 6.3 years) participated in the screening program. The prevalence of AF was 4.0% (95% CI 3.5%--4.7%) (*n =* 183), including 1.8% (95% CI 1.4%--2.2%) with ECG-confirmed known AF (*n =* 82), 1.7% (95% CI 1.4%--2.2%) with known AF in sinus rhythm (*n =* 79), and 0.5% (95% CI 0.3%--0.7%) with ECG-confirmed previously unknown AF (*n =* 22). In men as well as women, the prevalence of AF was higher with advancing age (*p* for trend \< 0.001 for both sexes, [Fig 1](#pmed.1003146.g001){ref-type="fig"}). The 183 patients with AF were older, taller, and more likely to be male and had a higher prevalence of prior stroke or TIA, coronary heart disease, and congestive heart failure (*p* \< 0.02, [Table 1](#pmed.1003146.t001){ref-type="table"}). The heart rate of those with AF was higher (*p* \< 0.001). Body mass index, blood pressure, prevalence of smoking, alcohol intake, hypertension, and diabetes mellitus or use of antihypertensive drugs did not differ between the 2 groups. Patients with new AF were older than those with known AF (77.5 ± 7.8 years versus 74.7 ± 7.7 years, *p* = 0.07) and had lower CHA~2~DS~2~-VASc scores (3.0 ± 1.3 versus 3.5 ± 1.6, *p* = 0.08), though the differences were not statistically significant. The majority of new AF cases (18/22) had no symptoms, whereas 4/22 complained of shortness of breath and dizziness.

![Prevalence of atrial fibrillation according to age and sex.](pmed.1003146.g001){#pmed.1003146.g001}

10.1371/journal.pmed.1003146.t001

###### Characteristics of the study population.

![](pmed.1003146.t001){#pmed.1003146.t001g}

  Characteristic                           AF (*n =* 183)   Non-AF (*n =* 4,348)   *p*
  ---------------------------------------- ---------------- ---------------------- ---------
  Women, *n* (%)                           86 (47.0)        2,444 (56.3)           0.01
  Age, years                               74.8 ± 7.3       71.4 ± 6.3             \<0.001
  Body height, cm                          161.3 ± 9.8      159.7 ± 8.8            0.02
  Body mass index, kg/m^2^                 24.9 ± 4.2       24.6 ± 3.5             0.30
  Systolic blood pressure, mm Hg           134.5 ± 18.4     136.6 ± 18.8           0.13
  Diastolic blood pressure, mm Hg          73.6 ± 11.0      73.6 ± 9.4             0.99
  Heart rate, beats/min                    78.1 ± 16.5      73.7 ± 10.9            \<0.001
  Current smoking, *n* (%)                 17 (9.4)         596 (13.8)             0.10
  Alcohol intake, *n* (%)                  24 (13.3)        493 (11.4)             0.43
  Hypertension, *n* (%)                    114 (62.3)       2,444 (56.2)           0.10
  Use of antihypertensive drugs, *n* (%)   101 (55.2)       2,277 (52.4)           0.13
  Diabetes mellitus, *n* (%)               50 (27.3)        1,007 (23.2)           0.20
  History of cardiovascular disease                                                
      Coronary heart disease, *n* (%)      25 (13.6)        271 (6.2)              \<0.001
      Congestive heart failure, *n* (%)    5 (2.7)          18 (0.4)               \<0.001
      Stroke or TIA, *n* (%)               45 (24.6)        704 (16.6)             0.004

Values are means ± standard deviation or number of participants (% of column total).

Abbreviations: AF, atrial fibrillation; TIA, transient ischemic attack.

Management of AF at baseline {#sec015}
----------------------------

The majority of the patients with AF (155/183, 85%) had a class 1 recommendation for OAC therapy \[[@pmed.1003146.ref005]\]: specifically, 138/161 (86%) known AF and 17/22 (77%) new AF ([Fig 2](#pmed.1003146.g002){ref-type="fig"}). Of the OAC-eligible patients, 11.0% (17/155) had a HAS-BLED score ≥ 3, and 4 patients with known AF had previously stopped warfarin because of bleeding (2 retinal hemorrhage, 2 hematuria). OAC prescription rate (for those with a class 1 recommendation) was 20% (28/138) in known AF patients and 0% in new patients with AF ([Fig 2](#pmed.1003146.g002){ref-type="fig"}). Of the 28 patients on OAC therapy (24 warfarin, 4 dabigatran), 5 patients had been prescribed warfarin after valve implantation. Therefore, OAC was taken by only 17% of patients with AF (23/133) without implanted heart valves (22/70 patients in AF rhythm \[31%\] versus 1/63 in sinus rhythm \[2%, *p \<* 0.001\]). In those who were taking warfarin, the majority (14/17, 82%) had recent INR values between 2.0 and 3.0. Thirty patients (27.5%) were on antiplatelet therapy only: aspirin (15%), clopidogrel (9%), and aspirin plus clopidogrel (4%). Antiarrhythmic agents were more often used in known AF in sinus rhythm (25% versus 7%), whereas rate control medications were more common for those with known AF in AF rhythm (60% versus 30%, [Table 2](#pmed.1003146.t002){ref-type="table"}).

![The flow chart of patients with AF.\
\*Patients with AF of CHA~2~DS~2~-VASc ≥ 2 (men) or ≥ 3 (women). AF, atrial fibrillation; LAAO, left atrial appendage occlusion; OAC, oral anticoagulant; ICH, intracerebral hemorrhage.](pmed.1003146.g002){#pmed.1003146.g002}
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###### Management of AF in patients eligible for oral anticoagulant therapy[\*](#t002fn001){ref-type="table-fn"} (*n =* 155).

![](pmed.1003146.t002){#pmed.1003146.t002g}

  ------------------------------------------------------------- ----------------------- -------------------------- -----------------------
  Characteristic                                                Known AF in AF rhythm   Known AF in sinus rhythm   Previously unknown AF
                                                                *n =* 75                *n =* 63                   *n =* 17
  Men, *n* (%)                                                  37 (49)                 32 (51)                    11 (65)
  Age, years                                                    75.6 ± 7.7              74.7 ± 7.9                 80.2 ± 6.4
  AF duration, years                                            10.1 ± 10.7             5.6 ± 5.7                  0
  CHA~2~DS~2~-VAScscore                                         4.0 ± 1.5               4.0 ± 1.5                  3.5 ± 0.9
                                                                Baseline                Baseline                   12-month follow-up
  *n* (%)                                                       *n =* 75                *n =* 63                   *n =* 15
  AF catheter ablation                                          5 (7)                   10 (16)                    1 (7)
  Antiarrhythmic agents[^§^](#t002fn002){ref-type="table-fn"}   5 (7)                   16 (25)                    4 (25)
  Rate control                                                  45 (60)                 19 (30)                    8 (47)
      Digoxin                                                   20 (27)                 4 (6)                      2 (11)
      β-Blocker                                                 35 (47)                 17 (27)                    8 (42)
  Oral anticoagulant                                            25 (33)                 3 (5)                      0
      Warfarin                                                  22 (29)                 2 (3)                      0
      Dabigatran                                                3 (4)                   1 (2)                      0
  Antiplatelet drugs only                                       18 (24)                 20 (32)                    5 (33)
      Aspirin                                                   12 (16)                 9 (14)                     3 (20)
      Clopidogrel                                               5 (7)                   7 (11)                     2 (11)
      Dual antiplatelet                                         1 (1)                   4 (6)                      0
  ------------------------------------------------------------- ----------------------- -------------------------- -----------------------

\*Patients with AF of CHA~2~DS~2~-VASc ≥ 2 (men) or ≥ 3 (women).

^§^Antiarrhythmic agents = propafenone or amiodarone.

Abbreviation: AF, atrial fibrillation

All 127 patients with actionable AF (110 undertreated AF and 17 new AF) received education at the baseline visit. Education and advice on specialist referral were reinforced at 1 month in 108 participants, either during a community health clinic visit (*n =* 84) or via telephone consultation (*n =* 24).

Follow-up at 12 months {#sec016}
----------------------

Follow-up occurred in 148/183 patients at 12 months (81% complete): 96 were in person at the community health center, and 52 were by telephone. From the OAC-eligible patients, 126/155 (81%) were followed up, and 29 were lost to follow-up (21 unable to contact, 4 declined a phone interview, 2 had hearing difficulty and lived alone, and 2 had moved and were not available) ([Fig 2](#pmed.1003146.g002){ref-type="fig"}). At 12 months, 3 patients died (1 pneumonia, 1 heart failure, and 1 unknown causes), 3 had nonfatal stroke (2 ischemic and 1 intracranial hemorrhage), and 4 had experienced an acute coronary syndrome (no myocardial infarction) ([Fig 2](#pmed.1003146.g002){ref-type="fig"}). None of these patients were taking OAC, and only one of those who died was taking antiplatelet agents ([Fig 2](#pmed.1003146.g002){ref-type="fig"}).

In total, 103/127 patients with actionable AF were followed up at 12 months (81% complete), and only 17 attended cardiovascular specialist clinics, with 4 of these being prescribed OAC (warfarin for all 4 patients, [Fig 2](#pmed.1003146.g002){ref-type="fig"}). Most patients (*n =* 71) did not attend a specialist clinic and instead attended community health centers or outpatient services of smaller hospitals, where they were prescribed traditional Chinese medicine (*n =* 34) or antiplatelet agents (*n =* 12) or both (*n =* 3). Fifteen patients did not go to any doctors and did not take any antithrombotic drugs. For the 5 patients who underwent either left atrial appendage occlusion (*n =* 1) or catheter ablation (*n =* 4), dabigatran was prescribed 3 months before and after procedure and then discontinued. Of the 17 patients with new AF and a class 1 recommendation for OAC, only 3 attended a specialist clinic and, none were prescribed OAC ([Fig 2](#pmed.1003146.g002){ref-type="fig"}). Of the 28 patients with AF taking OAC at baseline, OAC was no longer taken in 4, including 3 in sinus rhythm versus 1 in AF rhythm ([Fig 2](#pmed.1003146.g002){ref-type="fig"}).

Discussion {#sec017}
==========

The main findings of our study are that AF is prevalent in Chinese people aged 65 years and older, with an overall prevalence of 4.0%, and that actionable AF constituted 2.8% of all those screened, a very high proportion in whom initiation of OAC therapy could make a difference to prognosis. Of those with known AF qualifying for guideline-recommended OAC prophylaxis, only 20% were taking OAC. The percentage was even lower (17%) when patients with valvular prostheses requiring warfarin were excluded, highlighting the significant undertreatment of AF in patients managed by community health centers. Ischemic stroke or death occurred in 5 patients (none were taking OAC) in 1 year, which was potentially preventable if guideline-recommended OAC had been used.

Our data highlight a serious public health issue in China with undertreatment of AF in the community, which is likely to result in an excess of preventable stroke and death. Our OAC treatment rates are lower than those reported in Chinese tertiary hospitals (9.6% to 68.4%) and nontertiary hospitals (4.0% to 28.2%) \[[@pmed.1003146.ref016]\]; however, our study may more closely reflect a real-world sample of the community-dwelling population aged ≥65 years in China. Despite providing education regarding AF and advice on specialist referral for all 127 patients with actionable AF, the majority did not attend a specialist clinic, and of the 17 who attended the specialist clinic, only 4 were commenced on OAC therapy.

Low prescription of OAC is complex and compounded by many factors, including (1) patient reluctance to attend because they did not consider themselves very ill, despite one-on-one education; (2) patients elected to attend their local community health center and believed their AF was adequately treated, even though they were only prescribed antiplatelet drugs and traditional Chinese medicine; and (3) community health center physicians may lack knowledge regarding evidence-based management of AF. Furthermore, there was also low adherence to AF guidelines by the specialists in the tertiary hospital clinics, which may be the result of (1) worries about patient treatment compliance to warfarin in the absence of a dedicated anticoagulant clinic or team in the local area; (2) the common misperception of aspirin efficacy and safety \[[@pmed.1003146.ref017],[@pmed.1003146.ref018]\]; (3) restricted use and/or unavailability of the new OACs (NOACs), even in some tertiary hospitals; and (4) the expense of NOACs may prohibit patient agreement to the prescription.

Education for both patients and physicians in the community health centers is required to overcome these barriers. It has been demonstrated across 5 countries that multifaceted education programs targeting both patients and providers can significantly increase the proportion of patients treated with OAC from 68% to 80% at 1 year \[[@pmed.1003146.ref019]\]. In China, it may be possible to run workshops providing simplified important information on AF. Workshops for patients should focus on disease education to improve health-seeking behaviors, whereas physician education should focus more on understanding evidence-based treatment for AF and establishment of direct and efficient referral pathways for patients to access appropriate treatment with a cardiologist. Directed health resource allocations for patients to access anticoagulant drugs and INR testing in community health centers, such as a regular specialist outreach clinic, may help enhance adherence and long-term persistence with OAC. Furthermore, public health policies that include NOACs into medical insurance will give both patients and doctors more alternatives to choose from \[[@pmed.1003146.ref020]\].

Designated pathways to treatment are very important if AF screening is to be undertaken. In AF screening studies, it is well documented that the success for guideline adherence to OAC treatment is influenced by the pathway to treatment offered within the study. In the Swedish STROKESTOP study, an OAC review with the study cardiologist was part of the screening process, and 99% were reviewed, resulting in 74% of people with actionable AF having OAC initiated \[[@pmed.1003146.ref021]\]. However, the Belgium Heart Rhythm Week study, which screened in the community and had a similar pathway to our study (i.e., providing advice for patients to consult their general practitioner or cardiologist), found that only 11.2% of eligible participants with actionable AF commenced OAC therapy \[[@pmed.1003146.ref022]\]. Recently, the Huawei Heart Study \[[@pmed.1003146.ref023]\], using a program of integrated AF management directed by a mobile AF application in China, reported that approximately 80% of OAC-eligible patients with AF were anticoagulated. However, in the Huawei Heart Study, there is a likely selection bias because participants all owned smartphones, were able to download the app, and chose to use smart wearable devices to monitor their own pulse rhythm. The cohort was much younger and likely had higher health literacy and interest in improving their health and, therefore, were more likely to respond to physician advice.

Our finding of a detection rate of 0.5% for new AF cases is comparable to the 0.5%--0.8% identified in other mass community screening programs using a single-time screen \[[@pmed.1003146.ref021],[@pmed.1003146.ref024]\]. However, we detected fewer cases of new AF than we anticipated compared with the result of 2.0% identified in 2011 in our previous study \[[@pmed.1003146.ref013]\]. The lower detection rate may be related to the fact that 82% of our participants had undergone an ECG in the past 2 years as part of the free annual health examinations (including a 12-lead ECG) in community health centers for people ≥65 years old, which have been organized and supported by the Chinese government over the past 5 years. This may support the notion that annual ECG checks indeed help to detect AF early. However, annual ECG checks or single-time handheld ECG screens may still underestimate the prevalence of AF because cases of paroxysmal AF may not be captured. Innovative approaches involving current mobile and wireless technologies to record multiple ECG snapshots with patient-activated handheld single-lead ECG devices may help improve the detection rate \[[@pmed.1003146.ref025]\]. This was demonstrated in the STROKESTOP study, where 0.5% new AF was identified with the first screen, and after 2 weeks of intermittent twice-daily screening, the yield of new AF increased to 3% \[[@pmed.1003146.ref021]\]. The Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation (REHEARSE-AF) study also identified a higher yield of 3.8% using 1--2 ECG recordings per week over 1 year \[[@pmed.1003146.ref026]\]. However, before more frequent or intensive screening for unknown AF could be recommended in China, greater effort must be made to increase OAC treatment in known AF.

There are some limitations to our study that warrant discussion. First, the screening was performed at a single time point, and some cases of paroxysmal AF may have been missed; thus, the detection rate of AF may be underestimated. Second, despite our strict follow-up procedures, the loss to follow-up was 19.1%. Third, our study protocol did not allow the research cardiologist to directly review and treat patients with OAC; however, this reflects the real-world pathway to treatment for community-based Chinese. Finally, we did not involve physicians in the community health centers into our screening and education program to encourage initiation of and adherence with OAC, which may also contribute to the low rate of referral.

Conclusions {#sec018}
===========

There is a noticeable gap in the detection and treatment of AF in the Chinese residents aged 65 and over in urban Shanghai. AF disease education and advice on specialist referral provided in our study was insufficient to close the treatment gap. Currently, to prevent AF-related stroke in China, greater efforts must be made to increase appropriate OAC therapy in known AF, such as more effective downstream management pathways and health resource allocations, before more frequent or intensive screening for unknown AF could be recommended.
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To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

Title- Please revise your title according to PLOS Medicine\'s style. Your title must be nondeclarative and not a question. It should begin with main concept if possible. \"Effect of\" should be used only if causality can be inferred, i.e., for an RCT. Please place the study design (\"A randomized controlled trial,\" \"A retrospective study,\" \"A modelling study,\" etc.) in the subtitle (ie, after a colon).

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

Abstract- please clarify that all patients had a single timepoint screen rather than repeated screens for AF? This point is pertinent for paroxysmal AF perhaps and that a single point screening is possibly an underestimate

Abstract methods and findings- the last sentence should be a limitation of your study design. If the lack of OAC initiation is a reflection of the healthcare system in China, this should not be listed as a limitation but in the conclusion section

Abstract- you note that only 17 out of 103 patients attended speciality clinics. Can you clarify if these individuals were not referred to a speciality centre or if they did not attend of their own accord? This will impact how you frame the conclusions

Line 2- is atrial fibrillation a growing problem? This implies that the incidence has increased. If this is true please provide a reference to support this and also reword for clarity

Methods-could you name the participating hospitals here? Shanghai is a bit state, you may want to highlight the participating communities via a map

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section. a) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript. b) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place. c) In either case, changes in the analysis\-- including those made in response to peer review comments\-- should be identified as such in the Methods section of the paper, with rationale.

Please ensure that the study is reported according to the STROBE guideline, and include the completed STROBE checklist as Supporting Information. Please add the following statement, or similar, to the Methods: \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).\" The STROBE guideline can be found here: <http://www.equator-network.org/reporting-guidelines/strobe/> When completing the checklist, please use section and paragraph numbers, rather than page numbers.

Methods- please provide a copy of the medical history, lifestyle questionnaire used

Methods- please do not use the phrase "elderly subjects" as 65 years and over constitutes a large age range

Abstract, introduction and methods- it is unclear if the educational "intervention" should be renamed since this is not a trial? Please also clarify if the education and advice was given to patients directly or given to community health centre staff.

Results- please provide details of how many patients at the community health centre were approached, how many declined to participate.

Throughout- please use lower case p for p- values

Throughout- where you mention ESC guidelines- please ensure you introduce ESC on first view

Line 108-113 this information should be provided much sooner and more clearly. Please also provide additional details about the education provided at baseline.

Conclusion- I would probably avoid the phrase \"big gap\" as this is subjective.

PLOS Medicine requires that the de-identified data underlying the specific results in a published article be made available, without restrictions on access, in a public repository or as Supporting Information at the time of article publication, provided it is legal and ethical to do so. Please see the policy at

<http://journals.plos.org/plosmedicine/s/data-availability>

and FAQs at

<http://journals.plos.org/plosmedicine/s/data-availability#loc-faqs-for-data-policy>

Throughout- please provide 95% CI along with p-values

Comments from the reviewers:

Reviewer \#1: Chen and colleagues used AliveCor to screen elderly Chinese patients for AF in Community Health Centers. They diagnosed newly detected AF in 0.5%, and actionable AF (either newly detected or undertreated known AF with high stroke risk) in 2.8%. Referrals were then made to specialty clinics for consideration of OAC. Disappointingly, not a single patient initiated OAC as a result of this screening program. This study is humbling and highlights the challenges to appropriate treatment with OAC for elderly Chinese patients. The authors appropriately discuss these numerous challenges.

The contribution of this study is incremental. As reviewed in the Discussion, many others have implemented more successful AF screening programs, resulting in effective initiation of OAC. The contribution here is mainly in highlighting the challenges to implementation of OAC in this specific population.

One could question the role of ECG screening in patients with known AF. If a patient is known to have AF and has not initiated OAC, why would another AliveCor ECG documenting AF help?

Consider adding this citation to your Discussion: Heart Rhythm. 2019 Aug;16(8):e59-e65.

Reviewer \#2: This is a statistical review of manuscript PMEDICINE-D-19-04467. The manuscript is very clear and well-written. I only have minor comments.

Line 76: \"For all analyses, a two-sided probability value \< 0.05 was considered statistically significant.\" In the statistical jargon, it is actually referred to as a two-sided \"p-value\".

Line 98: \"OAC medication rate was 20% in all patients with known AF at baseline (28/138 ESC guideline recommended for OAC)\". Can I just clarify that I understand the numbers correctly? There are 161 patients with known AF, and 183 patients with AF in total. 155/183 had CHA2DS2-VASc score \>= threshold. Then out of the 161 with known AF, 138 were guideline recommended and only 28 were taking AOC? Figure 2 is excellent by the way and all answers are there, but perhaps you could you provide the breakdown of the 155 in the text so that it\'s easier when you read and don\'t have the Figure in front of you.

Line 115: \"Follow-up occurred in 126/155 patients at 12-months\". Did you do the follow up only in the 155 patients who had CHA2DS2-VASc score \>= threshold? If yes, could you please clarify in the Methods why this is the case?

Line 119: there is a typo in the word \"stroke\" that is currently spelled as \"stoke\".

Reviewer \#3: Dear Authors

Thank you for preparing this manuscript. I enjoyed reading it.

You performed a single-arm study at community health centres the Shanghai area. You performed AF screening with a hand-held device. You found existing known AF in 3.5% of patients and new AF in 0.5% of patients. 2.8% of the overall population had AF that was not anti-coagulated. Over one year, a small proportion of patients attended specialist clinics and initiated OAC. You concluded that there was a significant gap between AF detection and treatment.

Your paper addresses and important issue. It is clear and easy to read. The design is generally appropriate. I think it is publishable. I do, however have a few comments that I believe would improve the study prior to publication. Most of these focus on the clarity of your methods and focusing on the findings of your study in the discussion.

I do think that this manuscript could benefit from English language editing.

Abstract

Methods and findings

You should be clear in the abstract that it was a single measurement for AF.

I don\'t agree with your statement that \"The main limitation of our study is that the investigators were not able to provide patients who needed OAC therapy with either warfarin or non-warfarin oral anticoagulants ..\" This is not a limitation of your study, but a limitation of your healthcare system and should be framed as such.

Study population

Can you please describe exhaustively and precisely how the program was advertised? Was it only by notice to the neighborhood committee and by placements of posters? If so, this sentence should read \"The screening program was publicized through official notices to the neighborhood committee and placement of posters in community health centers.\" The current wording makes it sound like there were other channels

Screening and intervention

Can you provide more description of the community health clinic? This would help with the generalizability and reproducibility off the study. Is it physician run? Are there other health professionals? Is this the usual place that study participants access primary care or is this more of a drop in?

Rather than state that the ECGs were reviewed by an \"investigator\" or by a \"the first author\", this should be framed in the context of qualifications. Was it an arrhythmia specialist, cardiologist who reviewed them?

Please provide a citation for OAC guidelines.

Can you provide a more detailed description of the educational intervention? Was there a standard script? Did you use any patient decision-making tools? Was it done by a physician or other health care professional? How did you re-contact them at 1 month? It may be reasonable to provide a general overview in the methods and a detailed overview in an appendix.

Can you describe the AF specialist clinics better? How many are there? Are they near the community health centres? Is the only place in the region where anticoagulants are prescribed? In most other countries, family physicians or generally practitioners are competent and comfortable with OAC prescription.

Results

The results section should begin with some broader statement of the eligible population. This is vital to understand the uptake of screening and the subset of the population that did participate. Can you provide some estimate of the number of potentially eligible persons in the cachement area of the clinic? Perhaps you have census data or some other estimate of the roster of patients at the community clinics?

The statement \"Because warfarin, non-Vitamin K oral coagulants, and INR testing are not available at these community health centers, patients were advised to attend specialist clinics for OAC

prescription with information on how to make an appointment.\" Does not belong in the results. It should be in the methods, with further detail as per my comment above.

Discussion

I think your discussion is too long. I would aim to shorten it by at least 33%

It is interesting that among patients with actionable AF \"only 17 attended cardiovascular specialist clinics and 4 of these were prescribed OAC\" That is a discouragingly low rate and suggests that there is another critical barrier at the level of the specialist clinic. This should be re-inforced and discussed.

You postulate reasons why patients did not attend specialist clinics, but only one of these are supported directly by the findings of your study or by references. You also postulate possible interventions that could help improve OAC adherence. This paragraph has the same issues.

These two paragraphs could be combined, shortenend and amended.

I don\'t think that the paragraph that begins \"Our community study found significant under-treatment of known AF in sinus rhythm ... is particularly useful. Given that you took only a single ECG and you don\'t have the power to do comparative statistics between the 3 groups, it is largely an over-interpretation of your data and it distracts from your overall message.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003146.r002

Author response to Decision Letter 0

16 Mar 2020

###### 

Submitted filename: Response_to_reviewer.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003146.r003
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Misra

Adya

Senior Editor

© 2020 Adya Misra

2020

Adya Misra

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

30 Apr 2020

Dear Dr. Wang,

Thank you very much for re-submitting your manuscript \"Detection rate and treatment gap for atrial fibrillation identified through screening and an education program in community health centers in China (AF-CATCH): a prospective cross-sectional study\" (PMEDICINE-D-19-04467R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by 3 reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by May 07 2020 11:59PM.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Title-the title currently indicates the education program was carried out in community health centres. Please consider revising to "Detection rate and treatment gap for atrial fibrillation identified through screening in community health centers in China (AF-CATCH): a prospective cross-sectional study"

Abstract

Please add brief participant demographics

Methods

INR testing? please define on first view

Informed consent-please mention details of consent within the methods section

Please also mention any additional follow-up after the 12 month follow-up. If patients were still not on OACs but have AF, were they referred to a specialist clinic again?

Table1 -- p-values to three decimal places is sufficient

The excel file containing de-identifying data contains data that may breach patient confidentiality such as date of birth. Please remove this information for privacy reasons and deposit these files with your local research ethics committee instead. The data availability statement should be revised to note that there are ethical restrictions on data sharing.

Also, at this point please amend the statement in your methods section "All the records and information on participants were anonymized and de-identified before the analysis" as these do not appear to be de-identified medical records.

STROBE checklist- please check the provided checklist and corresponding paragraph numbers as they do not match the main text. For instance, you say example the discussion is in paragraph 7, but it\'s not. Please correct and clarify this.

Comments from Reviewers:

Reviewer \#1: While my concerns remain about the incremental contribution beyond previous screening studies and the lack of success in initiating anticoagulation, the authors have made an extensive effort to revise this manuscript and address all reviewer comments.

Reviewer \#2: This is a statistical review of manuscript PMEDICINE-D-19-04467_R1. I thank the authors for their answers for my previous comments, which are satisfactory. I do not have further comments.

Reviewer \#3: Thank you for allowing me to review a revised version of your manuscript.

You have satisfactorily addressed all of the comments I raised in my first review and you have submitted a greatly improved paper.

I have one final comment that stems from a change you made between the original submission and first submission.

Your title describes the study as a prospective, cross-sectional study.

Prospective is correct, but cross-sectional is not.

Prospective refers to measuring an exposure at baseline (in your case AF) and then an outcome (OAC use) at some point in the future.

Cross-sectional would mean you measured them both at a single time point.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003146.r004

Author response to Decision Letter 1

10 Jun 2020
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Submitted filename: Response_to_reviewers.doc

###### 

Click here for additional data file.
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16 Jun 2020

Dear Prof. Wang,

On behalf of my colleagues and the academic editor, Dr. William McIntyre, I am delighted to inform you that your manuscript entitled \"Detection rate and treatment gap for atrial fibrillation identified through screening in community health centers in China (AF-CATCH): a prospective multi-center study\" (PMEDICINE-D-19-04467R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: I have read the journal\'s policy and the authors of this manuscript have the following competing interests: BF reports grants, personal fees, and non-financial support from Bayer; grants, personal fees, and non-financial support from BMS-PFizer; personal fees and non-financial support from Daiichi-Sankyo, outside the submitted work; and personal fees and non-financial support by Omron. The remaining authors have declared that no competing interests exist. AliveCor provided ECG Heart Monitors for study purposes: the investigators are not affiliated with or have any financial or other interest in AliveCor.
